145 related articles for article (PubMed ID: 9517505)
1. Influence of malignant cell clonogenic capacities and position along the maturation pathway on their susceptibility to lymphokine-activated killer cell cytotoxicity.
Thomas X; Anglaret B; Adeleine P; Maritaz O; Bailly M; Fiere D; Archimbaud E
Leuk Lymphoma; 1998 Jan; 28(3-4):343-53. PubMed ID: 9517505
[TBL] [Abstract][Full Text] [Related]
2. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
[TBL] [Abstract][Full Text] [Related]
3. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
Komatsu F; Kajiwara M
Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
[TBL] [Abstract][Full Text] [Related]
4. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
Bendall LJ; Kortlepel K; Gottlieb DJ
Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
[TBL] [Abstract][Full Text] [Related]
7. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
Teichmann JV; Ludwig WD; Thiel E
Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
[TBL] [Abstract][Full Text] [Related]
8. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
9. Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells.
Fujiwara T; Loudon WG; Grimm EA
Lymphokine Cytokine Res; 1993 Feb; 12(1):45-8. PubMed ID: 8096153
[TBL] [Abstract][Full Text] [Related]
10. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.
Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A
Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
12. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
[TBL] [Abstract][Full Text] [Related]
13. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity.
Chao TY; Jiang SY; Shyu RY; Yeh MY; Chu TM
Br J Cancer; 1997; 75(9):1284-90. PubMed ID: 9155047
[TBL] [Abstract][Full Text] [Related]
15. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
Lefor AT; Rosenberg SA
J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427
[TBL] [Abstract][Full Text] [Related]
16. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of B16 melanoma sublines to lymphokine-activated killer cells as determined by 51Cr-release and clonogenic assays.
Tzeng JJ; Barth RF
J Immunol Methods; 1990 Apr; 128(2):257-66. PubMed ID: 2324514
[TBL] [Abstract][Full Text] [Related]
18. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(5):263-9. PubMed ID: 9802061
[TBL] [Abstract][Full Text] [Related]
19. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
20. Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants.
Gross N; Favre S; Beck D; Meyer M
Int J Cancer; 1992 Aug; 52(1):85-91. PubMed ID: 1354203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
